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in Acute and Chronic Type B
Aortic Dissection*
Santi Trimarchi, MD, PHD,y Kim A. Eagle, MDzT he temporal course of type B aortic dissec-tion (TBAD) can be divided into severalphases: hyperacute (<24 h), acute (within
2 weeks), subacute (2 weeks up to 3 months),
and chronic (>3 months) (1–3). This distinction has
become highly important, because it may help to
identify the time interval during which these patients
are at higher risk for complications and, for selected
patients, the optimal moment for TEVAR (Thoracic
Endovascular Aortic Repair). Identiﬁcation of both
the optimal cohort and most ideal time to perform
TEVAR remains a matter of debate.
The VIRTUE trial suggested that ideal timing of
TEVAR should be in the subacute phase, when
the aorta still has aortic plasticity, which leads to
similar remodeling and survival rates compared with
treatment in the acute setting (3). In addition, it may
also be that the incidence of TEVAR-related compli-
cations, like retrograde dissection, is reduced by
waiting a period of weeks after acute type B dissection.
In chronic TBAD, anatomic ﬁndings, such as nar-
row lumens and thickening of the intimal ﬂap, may
inhibit optimal aortic remodeling after TEVAR (4).
Although open repair has higher operative mortality
and morbidity, the previously noted anatomic issues
are not insurmountable. However, no deﬁnitive evi-
dence currently exists to conﬁrm which method is
optimal in uncomplicated type B dissection.*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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complicated TBAD is felt to be TEVAR, whereas open
surgery is reserved for younger patients, patients with
connective tissue disease such as Marfan syndrome,
and those unsuitable for endovascular repair. For un-
complicated type B dissection, there is an ongoing
debate regarding the most suitable therapy: medical
therapy alone or endovascular along with optimal
medical treatment. Although the ADSORB (Acute
Dissection treatment with Stent graft OR Best medical
therapy) and INSTEAD (the INvestigation of STEnt
grafts in Aortic Dissection) trials showed long-term
beneﬁts of TEVAR in terms of survival and remodel-
ing (5,6), several critiques have been published about
these trials, mainly regarding small sample size and
the primary outcome measures. Because of this, a
conservative approach for many patients with un-
complicated TBAD is still encouraged.
In chronic TBAD, the indication for treatment is
usually aneurysmal degeneration of the dissected
segments of the aorta after initial medical therapy,
which extends into the abdominal of the aorta in
almost two-thirds of these patients (7–9).
After standard TEVAR, which includes stent graft
treatment limited to the descending aorta, complete
false lumen thrombosis during follow-up is described
between 39% and 100% of patients (10), and rates of
favorable aortic remodeling range between 5% and
89% (11–13). In these patients, despite remodeling
in the proximal stented sections, distal segments of
the aorta may still be patent.SEE PAGE 183In the paper by Fanelli et al. (14) in this issue
of JACC: Cardiovascular Interventions, predictors
and inﬂuencing factors of remodeling and outcome
after TEVAR for both acute and chronic TBAD are
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193addressed. They used the “old” deﬁnition of acute
and chronic (#14 or >14 days after onset). The re-
sults could have been different if they had used truly
chronic patients, namely after 3 months from the
onset of symptoms. The factors they assessed are
interesting, because some of these have not been
studied well before, such as oversizing, the stent, left
subclavian artery embolization, and length and
number of implanted devices. Interestingly, over-
sizing did not inﬂuence the occurrence of endoleaks,
remodeling, or major adverse events, although 2
cases of retrograde dissection were reported in the
acute cohort. Furthermore, the length of coverage
did not have any inﬂuence on remodeling. In chronic
dissections, it may be expected that the length of
coverage would be of importance in type IIIb pa-
tients, because a patent abdominal aortic segment
may lead to aortic growth and inhibition of favorable
aortic remodeling. In the current results, however,
endoleaks were not related to the degree of false
lumen thrombosis in the chronic patients.
A signiﬁcant enlargement of the aortic diameter
above the stent graft was seen in the acute group,
which is important because this may reﬂect increased
strain on the aorta in the segments adjacent to the
stent graft. This effect of the stent graft on the aorta
and its hemodynamic surroundings should be studied
in more detail.
The observation that left subclavian artery embo-
lization was protective against endoleak develop-
ment in acute cases is interesting, because it
promoted false lumen thrombosis. This was not
observed in the chronic TBAD cohort.
Of course, these results need to be interpreted
carefully, because it is a retrospective case series with
a limited number of patients, including 5 cases of
post-traumatic dissection that per se are thought to
have a different etiology, prognosis, and evolution
than spontaneous dissection. It seems pretty clear
that precise characterization of the temporal events,
including the exact time between the onset and the
intervention, is critical. It appears that TEVAR in a
2-day-old and 3-week-old dissection can give signiﬁ-
cantly different results compared with a 12-month-
old dissection in terms of stent graft–related risks,
aortic remodeling, and technical success. The focus of
the current paper is on diameter only; however, a
volumetric analysis of the true and false lumen and
the size and precise location of the entry tear would
have added even more value to the paper, because
this gives a more clear indication of the changes in
both lumens after TEVAR.Nevertheless, given the paucity of studies looking
at this cohort, this paper adds to the knowledge and
understanding of the differences between TEVAR for
acute and chronic type B aortic dissections in terms of
management and remodeling.
Usefulness of an uncovered stent graft in the
abdominal aorta following standard TEVAR has
become a viable option for treating complicated
acute TBAD with malperfusion (15). Mid-term out-
comes in this group of patients have been asso-
ciated with promising results in terms of aortic
remodeling; however, no randomized and con-
trolled studies have been reported on its routine
use.
Branched and fenestrated TEVAR has also
become an emerging technique to treat patients
with chronic TBAD with less favorable anatomy
with endovascular management (16). These devices,
which are patient-speciﬁc with dedicated fenestra-
tions and branches, provide an opportunity to treat
a larger cohort of patients with less invasive tools.
Early reports surrounding branched and fenestrated
TEVAR seem promising, but long-term results in
the thoracic aorta are limited. Studies of larger
cohorts with longer follow-up are widely antici-
pated. Currently, these devices can only be used in
an elective setting, because the patient-speciﬁc
fabrication takes time. In the future, it is conceiv-
able that off-the-shelf branched and fenestrated
devices will become available to treat emergent
cases as well.
In addition to off-the-shelf devices, development
of branched and fenestrated stent grafts speciﬁcally
for chronic TBADs are needed, because continued
perfusion of the distal aortic segments is often
described, and stenting a longer section of the
descending aorta may be necessary. This represents
a problem with the current stent grafts, because
they are not designed to also cover the visceral
segments.
The entire ﬁeld of TEVAR for aortic dissection is
rapidly evolving. We need better technology, more
randomized trials, and more precise phenotyping as
we strive to optimize patient outcomes.
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